Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Drug Delivery: Enteral Route01:18

Drug Delivery: Enteral Route

2.9K
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
2.9K
Drug Delivery: Parenteral Route01:29

Drug Delivery: Parenteral Route

2.8K
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
2.8K
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

137
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
137
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

172
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
172
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

164
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
164
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

168
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
168

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Molecular N-Type Doping Unlocks Low-Threshold Nanosecond Lasing in a Microcavity-Integrated OLED Toward Electrically Pumped Organic Lasers.

Angewandte Chemie (International ed. in English)·2026
Same author

Cancer-associated fibroblasts in bladder cancer: Immunosuppressive mechanisms and therapeutic targeting.

Seminars in oncology·2026
Same author

Miniature photoelectric 3D force sensor with integrated LED-PD transceivers.

Optics letters·2025
Same author

Genetic modulation of ABCB1: Sunvozertinib reverses ABCB1-mediated multidrug resistance in cancer cells.

Cancer genetics·2025
Same author

Control of Rice Sheath Blight by Combining Susceptible Genes Editing and Nano-Immune Inducer Spraying.

Plant biotechnology journal·2025
Same author

Spin-Polarized Lasing via Ferromagnetic Spin Filtering in Hybrid Perovskites.

Journal of the American Chemical Society·2025

Video Experimental Relacionado

Updated: May 3, 2026

Delivery of Antibodies into the Murine Brain via Convection-enhanced Delivery
08:22

Delivery of Antibodies into the Murine Brain via Convection-enhanced Delivery

Published on: July 18, 2019

8.2K

Un medicamento enjaulado permite la entrega de precisión

Yuhao Xie1, Zhe-Sheng Chen1

  • 1Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, USA.

Science (New York, N.Y.)
|June 26, 2025
PubMed
Resumen

La tecnología GlycoCaging aprovecha las bacterias intestinales para activar medicamentos específicos para el tratamiento de la enfermedad inflamatoria intestinal (EII). Este enfoque dirigido tiene como objetivo mejorar la eficacia del tratamiento y reducir los efectos secundarios en pacientes con EII.

Más Videos Relacionados

Microinjectrode System for Combined Drug Infusion and Electrophysiology
08:30

Microinjectrode System for Combined Drug Infusion and Electrophysiology

Published on: November 13, 2019

9.0K
Author Spotlight: Surgical Methods and Outcomes in Oviductal Cloned Pig Embryo Transfers
05:41

Author Spotlight: Surgical Methods and Outcomes in Oviductal Cloned Pig Embryo Transfers

Published on: October 18, 2024

1.6K

Videos de Experimentos Relacionados

Last Updated: May 3, 2026

Delivery of Antibodies into the Murine Brain via Convection-enhanced Delivery
08:22

Delivery of Antibodies into the Murine Brain via Convection-enhanced Delivery

Published on: July 18, 2019

8.2K
Microinjectrode System for Combined Drug Infusion and Electrophysiology
08:30

Microinjectrode System for Combined Drug Infusion and Electrophysiology

Published on: November 13, 2019

9.0K
Author Spotlight: Surgical Methods and Outcomes in Oviductal Cloned Pig Embryo Transfers
05:41

Author Spotlight: Surgical Methods and Outcomes in Oviductal Cloned Pig Embryo Transfers

Published on: October 18, 2024

1.6K

Área de la Ciencia:

  • Microbiología
  • Farmacología
  • Gastroenterología

Sus antecedentes:

  • Las enfermedades inflamatorias intestinales (EII) incluyen la enfermedad de Crohn y la colitis ulcerosa, caracterizadas por inflamación intestinal crónica.
  • Las terapias actuales para la EII a menudo carecen de especificidad, lo que lleva a efectos secundarios sistémicos y eficacia limitada.
  • La administración dirigida de medicamentos sigue siendo un desafío importante en el manejo de la EII.

Objetivo del estudio:

  • Introducir y evaluar el GlycoCaging, un nuevo sistema de administración de medicamentos.
  • Para demostrar la capacidad de las bacterias intestinales para activar agentes terapéuticos específicamente dentro del entorno intestinal inflamado.
  • Evaluar el potencial de GlycoCaging para mejorar el tratamiento de la EII.

Principales métodos:

  • Desarrollo de pro fármacos de GlycoCaging diseñados para la división enzimática bacteriana.
  • Se utilizaron modelos in vitro e in vivo de inflamación intestinal.
  • Análisis de la cinética de liberación del fármaco y de la eficacia terapéutica en respuesta a la activación bacteriana.

Principales resultados:

  • Los prodrogas de GlycoCaging fueron efectivamente escindidos por bacterias intestinales específicas.
  • Los fármacos activados demostraron efectos antiinflamatorios localizados en modelos de EII.
  • El sistema mostró mejores resultados terapéuticos en comparación con la administración de fármacos convencionales.

Conclusiones:

  • GlycoCaging representa una estrategia prometedora para la activación de fármacos dirigidos en el intestino.
  • Este enfoque mediado por bacterias ofrece una nueva vía potencial para el tratamiento de la EII.
  • Se requiere más investigación para traducir el GlycoCaging en aplicaciones clínicas para la enfermedad inflamatoria intestinal.